Migraine Medication Escalation and Settlement Value for PI Attorneys

James Wong — Founder & CEO, LienScripts | March 29, 2026 | 7 min read

The OTC-to-triptan-to-CGRP medication escalation pattern in post-traumatic migraine cases directly maps to injury severity and settlement value. This guide explains how each treatment step strengthens the demand package and why the pharmacy record is the strongest timeline evidence available.

The medication escalation pattern in post-traumatic migraine — from over-the-counter analgesics to triptans to CGRP agents — is one of the most reliable pharmacological indicators of worsening neurological injury after an accident. Each step up in treatment intensity represents a clinical determination that the patient's condition exceeded the prior therapy's capacity, and the pharmacy record captures every step with dates, doses, and prescriber information that no subjective pain diary can match.

• Migraine medication escalation follows a predictable OTC → triptan → CGRP pathway, with each step documenting treatment failure at the prior level and increasing injury severity
• The American Headache Society treatment guidelines recommend stepwise escalation, meaning each new prescription reflects evidence-based clinical necessity — not provider preference (AHS Position Statement, 2019)
• LienScripts covers every medication in the escalation pathway on pharmacy lien, and each case receives a MERIT (Medication Evaluation & Rationale for Injury Treatment) report that maps the complete escalation timeline for demand packages
• According to James Wong, PharmD, founder of LienScripts, "The escalation timeline is the most underutilized settlement tool in migraine cases — it converts subjective headache complaints into an objective pharmacological record"
• Cases reaching CGRP-level treatment consistently support higher settlement values because the pharmacy record documents chronic, treatment-resistant neurological injury

Step 1: OTC Analgesics — The Baseline

The first medications a post-traumatic migraine patient uses are almost always over-the-counter: acetaminophen, ibuprofen, or naproxen. These are appropriate initial treatment per AHS guidelines, but they document the lowest severity tier.

From a settlement perspective, OTC-only treatment suggests the headache is mild and self-limiting — exactly the narrative defense counsel will advance. The key documentation point is not that the patient used OTC medications, but when they stopped working.

[!KEY] The date when OTC analgesics stopped controlling the patient's migraines — documented by the first prescription-level medication — is the inflection point where the case transitions from "minor headache" to "neurological condition requiring medical management."

Step 2: Triptans — Prescription-Level Acute Treatment

When OTC medications fail, the treating provider prescribes a triptan — sumatriptan, rizatriptan, eletriptan, or others. Triptans are serotonin 5-HT1B/1D receptor agonists that target the specific pathophysiology of migraine (Tfelt-Hansen et al., Cephalalgia, 2000).

A triptan prescription documents several things simultaneously:

1. The provider diagnosed migraine (not tension headache — triptans are migraine-specific)
2. OTC medications were insufficient
3. The patient requires prescription-level intervention for individual attacks

The pharmacy record shows triptan fill frequency, which directly measures migraine frequency. A patient filling sumatriptan monthly has approximately 4-8 migraine days per month. A patient filling triptans every two weeks has a higher attack burden.

[!TIP] Request the full triptan dispensing history from the pharmacy. The fill frequency is a proxy for migraine frequency — a patient who refilled sumatriptan 9 tablets every 14 days has a documented attack burden that supports a chronic migraine diagnosis.

Step 3: Older Preventives — Daily Medication Commitment

When triptans manage individual attacks but the attacks come too frequently (typically 4+ days per month), the provider adds a daily preventive medication. Common older preventives include:

• Topiramate — anticonvulsant with FDA approval for migraine prevention
• Amitriptyline — tricyclic antidepressant used off-label at low doses
• Propranolol — beta-blocker with FDA approval for migraine prevention
• Venlafaxine — SNRI used off-label for migraine prevention

The addition of a daily preventive is a major severity escalation. It documents that the patient's migraine frequency is too high for as-needed treatment alone, requiring continuous pharmacological prophylaxis.

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "Daily preventive medication means the neurologist determined the patient will have migraines frequently enough that they need a drug in their system every day to reduce attack frequency. That is not a minor headache complaint."

Step 4: CGRP Agents — Biologic-Class Intervention

The final escalation step is a CGRP (calcitonin gene-related peptide) antagonist: Qulipta (atogepant), Nurtec ODT (rimegepant), or an injectable antibody like Aimovig (erenumab), Emgality, Ajovy, or Vyepti. CGRP agents were developed specifically for migraine through a novel mechanism targeting the CGRP pathway (Edvinsson et al., Nature Reviews Neurology, 2018).

A CGRP prescription documents the highest severity tier:

1. OTC medications failed
2. Triptans were insufficient for attack control or frequency was too high
3. At least one older preventive was tried and either failed or produced intolerable side effects
4. The patient requires the most advanced pharmacological intervention available

[!KEY] The four-step escalation — OTC failure → triptan prescription → preventive addition → CGRP agent — creates a documentary arc that maps directly to worsening injury. Each step is date-stamped in the pharmacy record, creating an objective timeline that defense experts cannot easily challenge.

How Escalation Affects Settlement Value

Tier 1: OTC Only (Lowest Value)

Defense will argue headaches resolved with conservative management. Settlement negotiations start from the weakest position.

Tier 2: OTC + Triptans (Moderate Value)

The case has prescription-level documentation. Defense concedes the patient had diagnosable migraine but may argue it was acute and self-resolving.

Tier 3: Triptans + Daily Preventive (Strong Value)

Daily medication commitment documents chronic migraine. The pharmacy record shows monthly refills of preventive medication — ongoing medical necessity.

Tier 4: CGRP Agent (Highest Value)

The patient has reached biologic-class therapy. The escalation record documents failed standard treatments, chronic disease, and the need for the most advanced intervention available. This tier consistently supports the highest settlement values in migraine cases.

Building the Demand Package Around Escalation

1. Create a medication timeline — list every migraine medication by date prescribed, organized chronologically. LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report that does this automatically.
2. Highlight transition dates — the date of each escalation step is a clinical determination of worsening severity
3. Calculate treatment duration — count the months from first prescription to current therapy. Post-traumatic migraine lasting beyond 12 months meets the ICHD-3 criteria for persistent post-traumatic headache
4. Document concurrent medications — a patient on both a daily CGRP preventive and an as-needed triptan has two migraine-specific medications documenting ongoing disease burden

[!TIP] In demand letters, present the escalation as a narrative: "Despite treatment with [prior medication], Mr./Ms. [Client]'s post-traumatic migraines worsened, requiring escalation to [next medication]." This narrative structure converts pharmacy data into a compelling severity story.

Medication Overuse Headache: Addressing the Defense Argument

Defense experts may claim the patient developed medication overuse headache (MOH) from excessive triptan or analgesic use. This argument can be countered:

• MOH is itself a consequence of the original post-traumatic migraine — the patient overused medications because the post-traumatic condition was severe
• The escalation to CGRP agents often resolves MOH, which is documented in the pharmacy record by decreased triptan use after CGRP initiation
• The International Headache Society recognizes MOH as a secondary condition that does not negate the primary headache diagnosis (ICHD-3, 2018)

Frequently Asked Questions

For comprehensive pharmacy lien coverage of all migraine medications in the escalation pathway, LienScripts provides pharmacy services for personal injury patients with no upfront cost.

Related Resources

• Post-Traumatic Migraine and CGRP Treatment: Attorney Guide
• CGRP Medications: A Complete Guide for Personal Injury
• Qulipta (Atogepant): Preventive Migraine Treatment After a Personal Injury
• Medication History Proves Injury Severity
• Prescription Timeline as Causation Evidence